Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko +31 more
wiley +1 more source
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. [PDF]
Morgan RD +44 more
europepmc +1 more source
Physiology‐Guided Drug‐Coated Balloon Angioplasty: What We Know and What is Yet to be Understood
Catheterization and Cardiovascular Interventions, EarlyView.
Marco Frazzetto +4 more
wiley +1 more source
Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden +12 more
wiley +1 more source
A minimal transcription factor network is sufficient to drive paclitaxel biosynthesis. [PDF]
Pan Q +7 more
europepmc +1 more source
With no effective drug‐based prevention strategies available for chemotherapy‐induced peripheral neuropathy (CIPN), research in neuroprotective approaches has grown. Of particular interest is mechanical compression, which may protect nerves by temporarily reducing blood flow during treatment. The authors here conducted a prospective trial in women with
Kadriye Başkurt +11 more
wiley +1 more source
Paclitaxel induced-mechanical hypersensitivity is associated with time-dependant pro-inflammatory galectin-3<sup>+</sup> macrophages accumulation in the dorsal root ganglia. [PDF]
Zeboudj L, Malcangio M.
europepmc +1 more source
De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley +1 more source
Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023. [PDF]
Petrie H +4 more
europepmc +1 more source
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus +60 more
wiley +1 more source

